Novel Target for the Treatment of Glaucoma

Technology #ua11-125

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Alan Marmorstein
Associate Professor, Ophthalmology & Vision Science
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Control of Intraocular Pressure by Modification of Soluable Adenylate Cyclase Activity


Invention: The technology is the manipulation of anterior chamber drainage in the eye by targeting unique pathways. Bicarbonate sensitive soluble adenylyl cyclase regulates the secretion of substances into the aqueous humor and resulting pressure. Deficiency in bicarbonate channel bestrophin-2 was shown to have a lower intraocular pressure.


Background: Glaucoma is the leading cause of blindness, affecting 2.2 million individuals in the United States. Current glaucoma treatment involves reducing intraocular pressure and reducing the resistance to drainage of aqueous humor. Carbonic anhydrase inhibitors, one of the drugs used to treat glaucoma, has a poorly understood role in regulating aqueous flow. Researchers at the University of Arizona have discovered a potential new pathway to reduce intraocular pressure via bestrophins. In the eye, bestrophins, which function as anion channels and regulators of calcium signaling, are located in non-pigmented ciliary epithelial cells.



  • Glaucoma treatment
  • Potential screening as a biomarker



  • A newly targeted pathway for glaucoma treatments

Licensing Manager: 

Rakhi Gibbons

(520) 626-6695